Sterling IMRES
Sign in
RecruitingInterventionalPhase 1 / Phase 2

Curcumin and Retinal Study

Curcumin and Retinal Amyloid-beta Pilot Study

This is a registered study tracked in the Sterling IMRES research watch. It is sponsored by Texas Tech University Health Sciences Center and run by the investigators named in the registry, not by Sterling IMRES. Details come from ClinicalTrials.gov, last updated 13 January 2026.

Summary

This small randomised study at Texas Tech University Health Sciences Center gives participants either a low or a high dose of curcumin for two weeks. Retinal imaging is used to see whether curcumin crosses into nervous tissue and attaches to amyloid proteins. Researchers also look at safety, blood levels and gut bacteria.

Objectives

  • Test whether two weeks of curcumin supplementation reaches the eye and binds amyloid beta, as seen on retinal imaging.
  • Assess safety, bioavailability and changes in the gut microbiome at low and high curcumin doses.

Methodology

Study design
Randomized, parallel assignment, triple-blind, primary purpose: other
Conditions
Bioavailability; Gut Microbiome; Safety
Interventions
Low curcumin group (drug); High curcumin group (drug)
Primary outcome
Retinal imaging- amyloid fluorescent intensity
Sample size
60 participants (estimated)
Locations
United States

Team

0

Related research

PublishedInterventionalPhase 3

Longitudinal Antimalarial Combinations in Uganda

University of California, San Francisco

This Phase 3 study followed a cohort of young children in Kampala, Uganda, treating each malaria episode with one of three randomised drug combinations: amodiaquine plus artesunate, amodiaquine plus sulfadoxine-pyrimethamine, or artemether-lumefantrine. Following children over time allowed comparison of efficacy and safety across repeated treatments. Several results papers are linked in the registry.

2004
UpcomingInterventionalPhase 1

A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults

University of Oxford

This University of Oxford Phase 1 study in Thailand will give healthy adult volunteers three regimens in randomised sequence: piperaquine alone, pyronaridine-artesunate alone, and all three drugs together. Each course runs for three days with follow-up and washout periods between regimens. The aim is to understand how the drugs interact before wider use of triple artemisinin-based combinations.

2026